首页> 外文期刊>International braz j urol >External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
【24h】

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1

机译:EORTC风险评分的外部验证预测经尿道患者的非肌肉侵入性膀胱癌阶段TA和T1的患者经尿道患者后复发

获取原文
获取外文期刊封面目录资料

摘要

Validate the EORTC risk tables in Brazilian patients with NMIBC. Methods: 205 patients were analyzed. The 6 parameters analyzed were: histologic grading, pathologic stage, size and number of tumors, previous recurrence rate and concomitant CIS. The time for first recurrence (TFR), risk score and probability of recurrence were calculated and compared to the probabilities obtained from EORTC risk tables. C-index was calculated and accuracy of EORTC tables was analyzed. Results: pTa was presented in 91 (44.4%) patients and pT1 in 114 (55.6%). Ninety-seven (47.3%) patients had solitary tumor, and 108 (52.7%) multiple tumors. One hundred and three (50.2%) patients had tumors smaller than 3 cm and 102 (40.8%) had bigger than 3 cm. Concomitant CIS was observed in 21 (10.2%) patients. Low grade was presented in 95 (46.3%) patients, and high grade in 110 (53.7%). Intravesical therapy was utilized in 105 (56.1%) patients. Recurrence was observed in 117 (57.1%) patients and the mean TFR was 14,2 ± 7,3 months. C-index was 0,72 for 1 year and 0,7 for 5 years. The recurrence risk was 28,8% in 1 year and 57,1% in 5 years, independently of the scoring risk. In our population, the EORTC risk tables overestimated the risk of recurrence in 1 year and underestimated in 5 years. Conclusion: The validation of the EORTC risk tables in Brazilian patients with NMIBC was satisfactory and should be stimulated to predict recurrence, although these may overestimated the risk of recurrence in 1 year and underestimated in 5 years.
机译:验证巴西NMIBC患者的EORTC风险表。方法:分析205例患者。分析的6个参数是:组织学分级,病理阶段,肿瘤的大小和数量,先前的复发率和伴随的顺式。计算第一次复发(TFR),风险评分和复发概率的时间,并与从EORTC风险表获得的概率进行比较。计算C折射率,分析了EORTC表的准确性。结果:PTA在91名(44.4%)患者中,PT1 114(55.6%)。九十七(47.3%)患者患有孤立的肿瘤,108例(52.7%)多种肿瘤。一百三(50.2%)患者的肿瘤小于3厘米,102(40.8%)大于3厘米。在21例(10.2%)患者中观察到伴随顺应性。低等级介绍95例(46.3%)患者,高品位110(53.7%)。 105例(56.1%)患者使用膀胱内疗法。在117例(57.1%)患者中观察到复发,平均TFR为14,2±7,3个月。 C-Index为0,72,为1年,0,7持续5年。 1年内复发风险为28,8%,5年内57,1%,独立于评分风险。在我们的人口中,EORTC风险表将在1年内高估复发风险并在5年内被低估。结论:巴西NMIBC患者EORTC风险表的验证令人满意,应刺激预测复发,尽管这些可能会高估1年内复发风险并在5年内被低估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号